Raj Mehra - 12 Jan 2024 Form 4 Insider Report for SEELOS THERAPEUTICS, INC.

Reporting relationship: President, Chief Executive Officer and Chairman of the Board of Directors, Director
Issuer ticker: N/A
Reported as of: 12 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jan 2024, 21:47:31 UTC
Prior SEC filing: 01 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Raj Mehra

Key filing fact

Raj Mehra filed Form 4 for SEELOS THERAPEUTICS, INC. on 17 Jan 2024.

Key facts

This page summarizes Raj Mehra's Form 4 filing for SEELOS THERAPEUTICS, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jan 2024, 21:47.

Change

Previous filing in this sequence was filed on 01 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SEEL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +70,383
Change %
Price: $0.000000
Shares after: 70,383
Date: 12 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,383
Exercise price: $1.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the option shall vest on January 12, 2025, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC remarks

President, Chief Executive Officer and Chairman of the Board of Directors